Skip to main content
. 2023 Jul 8;9(7):e18119. doi: 10.1016/j.heliyon.2023.e18119

Fig. 9.

Fig. 9

Particle characterization of ME and ME-lipid A co-formulations. (A) The size distribution of ME co-formulated with BECC438b and BECC438s does not appear to change substantially. (B) Likewise, the size distribution of ME co-formulated with BECC470b and BECC470s remains rather constant. (C) The zeta potentials for ME and the ME-lipid A co-formulations are different due to the negative charge contributes by the lipid A analogues.